Levesialle Continu 20 (Ethinylestradiol, Levonorgestrel | Lactose)

Ethinylestradiol, the estrogen component, suppresses the mid‑cycle luteinizing hormone surge, which helps prevent ovulation. It also contributes to stabilising the endometrial lining, supporting the overall contraceptive effect.

The dosing regimen for Levesialle Continu 20 is determined by the prescribing healthcare professional. Patients should follow the prescriber’s instructions and the product labeling for the correct schedule.

Levesialle Continu 20 is intended for use only when pregnancy is not present. It should not be started during pregnancy, and women who become pregnant should discontinue use. Breastfeeding mothers should consult their physician, as hormonal contraceptives may affect milk production.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levesialle Continu 20 contains the same active ingredients—ethinylestradiol and levonorgestrel—as many other combined pills, offering comparable efficacy and safety profiles. Differences may lie in dosage strengths, tablet size, or excipients, which can affect tolerability for individual users.

Store the tablets at ambient temperature, below 25 °C, in the original packaging. Protect them from moisture, direct sunlight, and excessive heat to maintain potency.

Levesialle Continu 20 is taken orally, usually once daily at the same time each day, as directed by a healthcare professional. The tablet should be swallowed whole with water and not chewed.

Serious risks include thromboembolic events such as deep‑vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. Rare but severe allergic reactions and significant liver dysfunction may also occur. Prompt medical attention is required if any of these symptoms arise.

Women with a history of thromboembolic disorders, uncontrolled hypertension, severe liver disease, known or suspected breast cancer, or who are smokers over 35 years old should avoid using Levesialle Continu 20. Consultation with a healthcare provider is essential to assess suitability.